Possibilities of using genetic knowledge in type 2 diabetes in clinical practice
Forum Diab 2019; 8(2): 150-152
The use of genetic knowledge has been used in the clinical practice of diabetology for several decades. These findings have so far been mainly used in the diagnosis and treatment of monogenic types of diabetes. Although genome-wide association studies have identified more than 100 gene variants associated with type 2 diabetes, the translation of these findings into clinical practice is still limited. In this paper, we present two examples of the transfer of genetic knowledge into clinical practice regarding the pharmacogenetics of metformin therapy and the possibility of using genetic scores to assess cardiovascular risk in patients with type 2 diabetes.
cardiovascular genetic score – genetics of type 2 diabetes – pharmacogenetics of metformin
- Zhou K, Yeah SW, Seiser EL et al. Variation in the glucose transporter gene SLC2A2 is associated with glykemic response to metformin. Nat Genet 2016; 48(9): 1055–1059. Dostupné z DOI: <http://dx.doi.org/10.1038/ng.3632>.
- Rathmann W Strassburger K, Bongaerts B et al. [GDS Group]. A variant of the glucose transporter gene SLC2A2 modifies the glycaemic response to metformin therapy in recently diagnosed type 2 diabetes. Diabetologia 2019; 62(2): 286–291. Dostupné z DOI: <http://dx.doi.org/10.1007/s00125–018–4759-z>.
- Morieri ML, Gao H, Pigeyre M et al. Genetic tools for coronary risk assesment in type 2 diabetes. A cohort study from the ACCORD clinical trial. Diabetes Care 2018; 41(11): 2404–2413. Dostupné z DOI: <http://dx.doi.org/10.2337/dc18–0709>.